VEGFA and neoplasm: Given VEGF’s crucial role in angiogenesis and its conspicuous expression in tumor and stromal cells, particularly in inflammatory cells of human tumors, the first developed angiogenesis inhibitor for clinical use targeted the VEGF signaling pathway [20].